Sarclisa (isatuximab-irfc) is a therapy generally used in combination with other medicines to manage multiple myeloma, a cancer affecting the bone marrow. It is considered relevant in clinical scenarios involving a specific patient population, such as newly diagnosed adults who are ineligible for transplant, and is applied in clinical settings that involve recurrent or episodic manifestations following prior management. This medication is generally applied across domains where additional symptomatic support is needed.

“The treatment supports patients during episodes of heightened discomfort and may help them cope more steadily with symptom fluctuations.”

Sustaining Disease Control and Remission

This medication helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by helping to ease the overall symptom load. It is relevant in contexts marked by increased discomfort or tension.

Enhancing Patient Comfort and Stability

Sarclisa is considered relevant in conditions characterized by periods of heightened symptoms, helping to provide supportive relief when symptoms interfere with routine activities. It assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Management in Relapsed or Refractory Cases

Commonly used across conditions presenting with acute episodes, Sarclisa is commonly used when symptoms intensify and supportive relief is needed. It is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

Regulatory References

1. European Medicines Agency overview of Sarclisa

Sarclisa (isatuximab-irfc) is an anti-cancer medicine indicated only for use in adult patients who have been diagnosed with Multiple Myeloma and meet specific criteria regarding prior lines of treatment or transplant eligibility. The medicine is strictly contraindicated for use in individuals who have experienced a severe hypersensitivity reaction to isatuximab-irfc or any of its ingredients. The regulatory documents define eligibility constraints across several key populations:

• SARCLISA is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients.
• The medicine is indicated for use only in adult patients.
• Safety and effectiveness in pediatric patients (<18 years of age) have not been established.
• No dose adjustment is recommended for patients with mild to severe renal impairment or mild hepatic impairment.
• Females who are able to become pregnant must use effective contraception during treatment and for 5 months after the last dose.

Use during pregnancy carries a risk of fetal harm, and the combination regimens are formally contraindicated. These requirements ensure the medicine is used within the patient populations where its official safety profile has been established.

Official Interaction Profile

Isatuximab-irfc is a large-molecule monoclonal antibody with an official regulatory designation of no expected clinically significant pharmacokinetic interactions (e.g., via CYP450 enzymes or common drug transporters) with co-administered medicines.

Interactions are defined by mandatory procedural and combination requirements, as well as interference with specific diagnostic testing.

---

Mandatory Co-administration and Restrictions

Classification	Constraint	Interacting Agents
Formal Contraindication	Co-administration is prohibited in pregnant women due to the teratogenicity of the partner drugs.	Pomalidomide or Lenalidomide
Therapeutic Combination	The product is required to be co-administered for therapeutic effect.	Pomalidomide, Carfilzomib, Bortezomib, Dexamethasone
Procedural Requirement	Premedication must be administered 15 to 60 minutes prior to the infusion.	Acetaminophen, Diphenhydramine, H2-antagonists
Physical Restriction	The product must not be administered concomitantly in the same intravenous line with any other medicinal product.	All other agents

---

Interactions with Diagnostic Tests

Isatuximab is officially documented to interfere with certain laboratory procedures, which can affect diagnostic outcomes:

• Serological Testing: The medicine may cause a false-positive Indirect Antiglobulin Test (Indirect Coombs Test) due to its binding to CD38 on red blood cells. This interference may persist for approximately six months after the last dose.
• M-Protein Monitoring: The drug may interfere with Serum Protein Electrophoresis (SPEP) and Immunofixation Electrophoresis (IFE) assays used to monitor endogenous M-protein, potentially impacting the accurate determination of complete response.

Targeted CD38 Binding and Direct Cytotoxicity

This mechanism is centered on the drug's role as a highly specific monoclonal antibody that binds precisely to the CD38 glycoprotein on the surface of malignant plasma cells. This specific binding triggers a direct, Fc-independent signal within the target cell, which initiates caspase-dependent apoptosis (programmed cell death). This action results in the rapid, systemic destruction and reduction of the primary CD38-expressing cell population.

---

Immune Effector Recruitment and Microenvironment Modulation

The drug's Fc region acts as a molecular bridge, recruiting host immune cells, specifically Natural Killer (NK) cells and macrophages. These cells engage in Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Phagocytosis (ADCP), enhancing the cellular destruction process. Furthermore, the drug modulates the immune response by inhibiting the CD38 ectoenzyme and depleting immunosuppressive CD38^+ regulatory T-cells. This action is mechanistically complemented by the simultaneous elimination of immunosuppressive components.

---

Mechanistic Constraints on Physiological Monitoring

As a direct consequence of its mechanism, the drug binds to CD38 present on normal Red Blood Cells (RBCs), leading to a structural interference that causes false-positive results in blood bank compatibility tests (Coombs test). Additionally, the drug itself is an IgG kappa protein, and its presence can structurally interfere with laboratory assays ( SPEP/ IFE) used to monitor protein levels, which technically interferes with the objective measurement of target protein levels.

Sarclisa (isatuximab-irfc) is administered exclusively as an intravenous (IV) infusion and must be overseen by a healthcare professional in a clinical setting. The medicine is provided as a concentrate that requires dilution into a 250 mL bag of 0.9% Sodium Chloride or 5% Dextrose Injection before infusion.

---

Dosing and Schedule Principles

The standard dose for Sarclisa is 10 mg/kg actual body weight, which is calculated before each treatment cycle. No dose reduction of Sarclisa is recommended, though dose delays may be implemented by the physician if certain toxicities occur.

Treatment follows a defined, cyclic schedule:

• Initial Phase (Cycle 1): Infusions are typically administered once weekly (Days 1, 8, 15, and 22).
• Maintenance Phase: The frequency transitions to once every two weeks (Days 1 and 15) for subsequent 28-day cycles in most regimens. For some longer regimens, the frequency may decrease to once every four weeks in later cycles.

Treatment is generally continued until disease progression or unacceptable toxicity.

---

Administration Conditions

To manage potential infusion-related reactions, premedication (including dexamethasone, acetaminophen, and H2 antagonists/diphenhydramine) must be given 15 to 60 minutes prior to starting the Sarclisa infusion.

The infusion rate is gradually escalated. The first infusion is the longest (approximately 3 to 4 hours), while subsequent infusions can be progressively shortened if no reactions occur. The solution must be administered using an in-line filter, and it must not be mixed or co-administered with other agents in the same IV line.

Population-Specific Rules: No dose adjustment is recommended for Sarclisa itself in older adults or in patients with mild to severe renal impairment or mild hepatic impairment.

Research Evidence / Overview of Studies for Sarclisa

---

Evidence for Use in Newly Diagnosed Multiple Myeloma (NDMM), Transplant-Ineligible

The key evidence for this use is derived from a large, randomized Phase 3 clinical trial (IMROZ). Research examined Sarclisa when given alongside a standard combination therapy regimen, comparing it against the standard regimen alone. The study populations focused on adults who had not received prior treatment for multiple myeloma and were considered unfit for autologous stem cell transplant. Researchers monitored time-based outcomes, such as Progression-Free Survival (PFS), and explored the rate of achieving very deep responses, like Minimal Residual Disease (MRD) Negativity. Findings describe patterns observed in the studies related to the PFS duration in the Sarclisa combination group compared to the control group.

---

Evidence for Use in Relapsed or Refractory Multiple Myeloma (RRMM)

The evidence for this use is based on two distinct large-scale Phase 3 clinical trials (ICARIA-MM and IKEMA). These studies were conducted to compare the Sarclisa combination regimens against established standard-of-care regimens in adults whose disease had returned or had not responded to prior treatments. Research explored the use of Sarclisa in two different combination therapies. Findings describe patterns observed in the studies related to disease progression duration in the combination groups compared to the control groups. Furthermore, the trials described the Overall Survival (OS) patterns; one key trial (ICARIA-MM) included a long-term data update for this outcome.

---

Long-Term Follow-up and Durability of Study Endpoints

This area addresses the extent of observation periods available in the main studies, specifically summarizing the reported follow-up durations for primary outcomes like Progression-Free Survival (PFS) and the maturity status of Overall Survival (OS) data. The main clinical trials included long-term follow-up to examine the PFS endpoint over extended time periods. While long-term data updates are available for some outcomes in the relapsed setting, the data for OS remains immature in the newly diagnosed, transplant-ineligible population.

---

Evidence in Specific Patient Groups

This section outlines which patient subgroups were specifically analyzed in the clinical trials, such as those with high-risk genetic features and older adults (ge 75 years old). Research also describes patterns in patients defined by their previous therapy, such as those who were refractory (non-responsive) to common existing treatments like lenalidomide, to ensure the results apply only to the populations studied.

---

Research Gaps and Uncertainties

Uncertainty related to the research base includes the immaturity of certain Overall Survival (OS) data in the newly diagnosed setting. Additionally, while subgroups were analyzed, subgroup findings are uncertain because those analyses were not the main focus of the large studies. Comparative evidence is lacking outside of the specific combination regimens tested, and evidence is limited when attempting to generalize to populations not specifically enrolled in the pivotal Phase 3 trials.

Key Studies & References

1. Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial

Sarclisa (isatuximab-irfc) concentrate must be stored under specific, controlled conditions as directed by regulatory labeling.

Vial Storage and Handling

Unopened vials must be kept in the refrigerator at 2 C to 8 C (36 F to 46 F). It is mandatory to keep the vial in the original carton to protect it from light. The concentrate must not be frozen and vials must not be shaken. The product must be stored out of the sight and reach of children.

Stability and Disposal

Once diluted for intravenous infusion, the solution is stable for up to 48 hours when refrigerated, followed by up to 8 hours at room temperature, which includes the infusion time. Sarclisa is for single-dose use only. Any unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.